Document is current
Any future updates will be listed below
-
Authors
Hoots, Jennifer K.
Webber, Heather E.
Nunez, Cecilia
Cooper, Jessica A.
Lopez-Gamundi, Paula
Lawlor, Victoria M.
Lane, Scott D.
Treadway, Michael T.
Wardle, Margaret C.
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (K08DA040006, 1F32DA048542)
“la Caixa” Foundation (LCF/BQ/DI19/11730047)
- License Information
-
More Information
Article History
Received: 22 February 2021
Accepted: 7 June 2021
First Online: 17 June 2021
Declarations
:
: In the past 3 years, MTT has served as a paid consultant to Avanir Pharmaceuticals and Blackthorn Therapeutics. MTT is a co-inventor of the EEfRT, which was used in this study. Emory University and Vanderbilt University licensed this software to BlackThorn Therapeutics. Under the IP Policies of both universities, MTT receives licensing fees and royalties from BlackThorn Therapeutics. In addition, MTT has a paid consulting relationship with BlackThorn. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict of interest policies, and no funding from these entities supported the current project. The authors declare no competing interests.
